Abintus Bio, Inc.

Abintus Bio is a preclinical stage gene therapy company that engages in the field of in vivo immune cell reprogramming. The company pursues products that modulate immune cells from within their native environment to enhance patient access and patient outcomes. It focuses on the discovery and development of a portfolio of first-in-class, product candidates that are designed to directly reprogram immune cells from within their native environment using proprietary vectors and related technologies.